Association between antivimentin/cardiolipin antibodies and pregnancy loss in pregnant women with at least one spontaneous miscarriage.

Abstract

Introduction: Antivimentin/cardiolipin antibodies (aVim/CL) have emerged as potential diagnostic markers for antiphospholipid syndrome, However, their association with pregnancy outcomes remains unclear. This study explores the clinical significance of aVim/CL in pregnancy loss.

Methods: A retrospective analysis was conducted on 429 pregnant women with at least one spontaneous miscarriage at The Third Affiliated Hospital of Wenzhou Medical University (October 2019- August 2022). Multivariable logistic regression and stratified analyses were utilized to assess the relationship between aVim/CL levels and pregnancy loss.

Results: Among the 429 participants, 79 experienced pregnancy loss, while 350 had live births. Elevated aVim/CL levels were associated with an increased risk of pregnancy loss, with an odds ratio (OR) of 1.108 (95% CI, 1.037-1.185). The area under the ROC curve (AUC) was 62.8, with a sensitivity of 77.2% and a specificity of 44%. A nonlinear L-shaped relationship was identified, with a threshold of 6.86 ng/mL, below which the risk of pregnancy loss significantly increased. No correlations were found between aVim/CL and coagulation or immune biomarkers.

Discussion: Elevated aVim/CL levels were identified as independent predictors of pregnancy loss in women with a history of spontaneous miscarriage. The threshold of 6.86 ng/mL may provide valuable clinical insights for risk stratification.